Drug intelligence / Profile preview

Otoact

Development stage: Unknown
Lead developer: Nextmune
Modality: Small Molecules
Administration: Otic, Topical

Overview

Otoact is a veterinary ear cleanser developed by Nextmune for use in dogs and cats. It is specifically formulated as a gentle ceruminolytic designed to dissolve excess earwax (cerumen) without irritating the ear canal. The product's primary active ingredient is squalene, a highly effective wax-dissolving agent, complemented by salicylic acid for its keratolytic and antiseptic properties. Additionally, it contains tannic acid as an astringent and Chamomilla recutita flower extract to provide soothing, anti-inflammatory relief to the ear lining. Otoact is used to maintain ear hygiene in companion animals prone to chronic wax buildup and as a supportive treatment for managing otitis externa.

Brand names: Otoact

Beyond the preview

Go deeper on Otoact.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Otoact.

Explore the full profile